S-minus-Levamisole-Levamisole-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemE(S)-(-)-LevamisoleCat.No.:HY-A0106CASNo.:14769-73-4Synonyms:Levamisole;L-Tetramisole;Levamisol分?式:C??H??N?S分?量:204.29作?靶點(diǎn):nAChR;Parasite作?通路:MembraneTransporter/IonChannel;NeuronalSignaling;Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(489.50mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM4.8950mL24.4750mL48.9500mL5mM0.9790mL4.8950mL9.7900mL10mM0.4895mL2.4475mL4.8950mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(12.24mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(12.24mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(12.24mM);ClearsolutionBIOLOGICALACTIVITY?物活性(S)-(-)-Levamisole(Levamisole)，?種驅(qū)?劑，具有免疫調(diào)節(jié)特性的。(S)-(-)-Levamisole作為α3β2(EC50=300μM)和α3β4(EC50=100μM)的正變構(gòu)調(diào)節(jié)劑(PAM))nAChRs的亞型。具有?服活性。體內(nèi)研究(S)-(-)-Levamisole(Levamisole)(50μg/mland200μg/ml;p.o.;30days)preventsweightgaininmicethatwerefedahighfatdiet[2].戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?RapidCommunMassSpectrom.2022Nov16;e9430.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].LewisJA,etal.Levamisole:APositiveAllostericModulatorfortheα3β4NicotinicAcetylcholineReceptorsPreventsWeightGainintheCD-1MiceonaHighFatDiet.CurrPharmDes.2017;23(12):1869-1872.[2].MehtaKP,etal.Immunoregulatorytreatmentforminimalchangenephroticsyndrome.ArchDisChild.1986;61(2):153-158.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel